Tcr2 Therapeutics Inc (NASDAQ:TCRR) Director Morana Jovan-Embiricos purchased 666,667 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was bought at an average price of $15.00 per share, with a total value of $10,000,005.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of TCRR stock traded up $0.06 during trading hours on Friday, reaching $15.19. The company had a trading volume of 807 shares, compared to its average volume of 165,848.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Further Reading: Net Asset Value
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.